Stage
Acquired | AcquiredAbout Mills Pharmaceuticals
Mills Pharmaceuticals owns the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide for the treatment of Essential Thrombocythemia (ET). GALE-401 (Anagrelide CR) contains the active ingredient anagrelide, an FDA-approved product, which has been in use since the late 1990s for the treatment of Essential Thrombocythemia (ET). GALE-401 is a reformulated, controlled release version of anagrelide that is currently only given as an immediate release (IR) version. Phase 1 studies have shown the drug to be effective at lowering platelet levels while reducing side effects that prevent patients from taking their therapy regularly.
Missing: Mills Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Mills Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Mills Pharmaceuticals Patents
Mills Pharmaceuticals has filed 10 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/14/2011 | 5/20/2014 | Architectural elements, Columns and entablature, Molecular biology, Mobile genetic elements, Missile guidance | Grant |
Application Date | 7/14/2011 |
|---|---|
Grant Date | 5/20/2014 |
Title | |
Related Topics | Architectural elements, Columns and entablature, Molecular biology, Mobile genetic elements, Missile guidance |
Status | Grant |
Latest Mills Pharmaceuticals News
Jan 14, 2014
US drugmaker Galena Biopharma revealed that it has acquired Mills Pharmaceuticals which has the worldwide rights to GALE401 Anagrelide CR a patented controlledrelease formulation of anagrelide.
Mills Pharmaceuticals Frequently Asked Questions (FAQ)
What is Mills Pharmaceuticals's latest funding round?
Mills Pharmaceuticals's latest funding round is Acquired.
Who are the investors of Mills Pharmaceuticals?
Investors of Mills Pharmaceuticals include Galena Biopharma.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.